COVID-19 Resource Community

ASTCT Resources for COVID-19

ASTCT Headquarters is closely monitoring the developing news about the Coronavirus (COVID-19) from the World Health Organization (WHO), Centers for Disease Control (CDC), and our community. We want you to know that we are placing the highest priority on the health and safety of all of our members and their patients and we will make decisions moving forward with the input of public health officials.

This community contains up-to-date information and resources to help you stay informed as the situation progresses. These resources are available to the public, however, you will need to log in to your ASTCT member account or create a guest account to participate in discussions or reply to blog posts. Click here to login or create a guest account. PLEASE NOTE: All users (member and guest) are required to accept the ASTCT terms of use and privacy policy when creating an account. Click here to learn more about using the features in this community.

Patient Guidelines

Members of ASTCT's Infectious Disease SIG have developed interim guidelines for COVID-19 management of HCT and cellular therapy patients. These guidelines will be modified as new information becomes available, including more data on epidemiology and clinical outcomes, and efficacy of drug therapies including clinical trial outcomes of novel therapeutics. Click here to view updated guidelines.

ASH-ASTCT COVID 19 Vaccine FAQs

The ASH-ASTCT COVID-19 Vaccination for HCT and CAR T cell recipients: Frequently Asked Questions were updated on 9/21/2021 and can be found here.

The authors of the FAQs are a team of experts representing both ASH and ASTCT. The team works together to develop this document which is updated periodically when new data become available. All current guidances are based on opinions of the ASTCT/ASH COVID-19 Vaccine expert panel.

Contributors to the FAQs document are: Fareed Khawaja, MD; Roy F. Chemaly, MD, PhD; Sanjeet Dadwal, MD; Steven A. Pergam, MD, MPH; John Wingard, MD; Jeffery Auletta, MD; Zeinab El Boghdadly, MBBCh; Maheen Abidi, MD; Alpana Waghmare, MD; Zainab Shahid, MD; Laura Michaels, MD; Joshua Hill, MD; Tobias M. Hohl, MD, PhD; Mini Kamboj, MD; Genovefa Papanicolaou, MD; and Michael Boeckh, MD.  

The General Principles of COVID-19 Vaccines for Immunocompromised Patients are available here.

The authors of the document are a team of experts representing both ASH and ASTCT. The team worked together to develop this document. All current guidances are based on the opinions of the ASTCT/ASH COVID-19 Vaccine expert panel.

Contributors are: Jeff Auletta, MD; Maheen Z. Abidi, MD Roy F. Chemaly, MD; Fareed Khawaja, MD; Mini Kamboj, MD, Genovefa Papanicolaou, MD; Josh Hill, MD; Julie Kanter, MD; Alpana Waghmare, MD; Adrian Wiestner, MD; John R. Wingard, MD, Jane Winter, MD; Laura C. Michaelis, MD, Sanjeet Dadwal, MD; Zeinab El Boghdadly, MD, Tobias Hohl, MD, PhD, Michael Boeckh, MD

Event Updates and Webinars

As this is an evolving situation, we will keep our website updated with the latest news and information related to all of our upcoming events. Additionally, due to travel restrictions related to COVID-19, some speakers at upcoming meetings will be required to present their sessions virtually. If you have any questions or concerns regarding your attendance at events, you may direct them to info@astct.org.

ASTCT is in the process of developing additional educational webinars to share updates and resources. Click here to view upcoming COVID-19 related content. Recordings of past webinars can be found here.

News and Updates

ASTCT and CIBMTR have issued a joint press release on guidelines and measures for combating COVID-19 and protecting transplant patients. Read it here. 

In addition to our educational resources, please visit NUCLEUS or this community's blog for more information and updates.

External Resources

As we receive additional patient guidelines, updates from the CDC or WHO, or policy updates, that information will be posted to the resource library within this community. 

CIBMTR Data Reporting for COVID-19: In an effort to inform centers, clinicians and patients about the impact of the pandemic on transplant and cellular therapy recipients, CIBMTR has made several alterations to forms and reporting to facilitate collection and dissemination of data on COVID-19 infections. See CIBMTR website for more details: www.cibmtr.org

The Transplant Associated Learning Network Team (TALNT) has an international COVID-19 Working Group used to aid in the exchange of institutional practices and resources regarding the current COVID-19 pandemic.  If you are interested in joining this network, please email Hannah Ingraham at Hannah.ingraham@cchmc.org.

Discussion Forum

You can use the discussion forum within this community to connect and share information and updates from within your institution.


footer dots

DISCUSSION FORUM

Discussion Forum

1 to 6 of 6 threads (15 total posts)
  Thread Subject Replies Last Post Status
COVID-19 vaccine
3 10 months ago by Jennifer Saullo
Original post by Jennifer Kanakry
Monoclonal antibodies under EUA
3 10 months ago by Dianna Howard
Original post by Brandon Hayes-Lattin
PPE for transplant recipients
3 one year ago by John McCarty
Original post by Jennifer Kanakry
WMDA guidance on COVID19 impact on registry operations
0 one year ago by Navneet Majhail
Discontinuation of in-home isolation for immunocompromised patients with COVID19
0 one year ago by Navneet Majhail
COVID-19 Resource Community
0 one year ago by Emily Bennett